Allergan beats second-quarter expectations, boosts full-year guidance

Growth in sales of anti-wrinkle treatment Botox and dermal filler Juvaderm helped drive Allergan Plc to an earnings beat on Tuesday, but gains were offset by a decline in Restasis and CoolSculpting sales.